Carregando...

A Phase 1/2 Study of evofosfamide, A Hypoxia-Activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

INTRODUCTION. The presence of hypoxia in the diseased bone marrow presents a new therapeutic target for multiple myeloma (MM). Evofosfamide (formerly TH-302) is a 2-nitroimidazole prodrug of the DNA alkylator bromo-isophosphoramide mustard that is selectively activated under hypoxia. A phase 1/2 stu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Principais autores: Laubach, Jacob P., Liu, Chia-Jen, Raje, Noopur S., Yee, Andrew J., Armand, Philippe, Schlossman, Robert L., Rosenblatt, Jacalyn, Hedlund, Jacquelyn, Martin, Michael, Reynolds, Craig, Shain, Kenneth H., Zackon, Ira, Stampleman, Laura, Henrick, Patrick, Rivotto, Bradley, Hornburg, Kalvis T.V., Dumke, Henry J., Chuma, Stacey, Savell, Alexandra, Handisides, Damian R., Kroll, Stew, Anderson, Kenneth C., Richardson, Paul G., Ghobrial, Irene M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6335171/
https://ncbi.nlm.nih.gov/pubmed/30279233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1325
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!